Oxford University and AstraZeneca's COVID-19 vaccine has hit its primary endpoint in a Phase III US trial.
The vaccine demonstrated a vaccine efficacy of one-hundred per cent at preventing severe disease and hospitalisation in the interim analysis, as well as seventy-nine per cent at preventing symptomatic COVID-19. Furthermore, the researchers highlighted that the vaccine efficacy was steady across age and ethnicity, with those aged sixty-five years and over indicating a vaccine efficacy of eighty per cent.
“Oxford University and AstraZeneca's COVID-19 vaccine has hit its primary endpoint in a Phase III US trial“
Also, no safety concerns related to the vaccine were identified by the independent data safety monitoring board (DSMB).
This compromised a thorough review of thrombotic events and cerebral venous sinus thrombosis with an independent neurologist's assistance.
Following this review, the DSMB identified no heightened risk of thrombosis or events correlated with thrombosis among the 21,583 participants who had received at least one dose of the vaccine.
Executive Vice President, BioPharmaceuticals R&D, Astra Zeneca, Mene Pangalos, stated: “These results add to the growing body of evidence that shows this vaccine is well tolerated and highly effective against all severities of COVID-19 and across all age groups. We are confident this vaccine can play an important role in protecting millions of people worldwide against this lethal virus. We are preparing to submit these findings to the US Food and Drug Administration and for the rollout of millions of doses across America, should the vaccine be granted US emergency use authorisation.”See all the latest jobs in Pharmaceutical